Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Gross Profit : $159.6 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Deciphera Pharmaceuticals Gross Profit?

Deciphera Pharmaceuticals's gross profit for the three months ended in Dec. 2023 was $46.5 Mil. Deciphera Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $159.6 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Deciphera Pharmaceuticals's gross profit for the three months ended in Dec. 2023 was $46.5 Mil. Deciphera Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $48.3 Mil. Therefore, Deciphera Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 96.30%.

Deciphera Pharmaceuticals had a gross margin of 96.30% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 9 years, the highest Gross Margin % of Deciphera Pharmaceuticals was 99.47%. The lowest was 93.46%. And the median was 97.34%.

Deciphera Pharmaceuticals Gross Profit Historical Data

The historical data trend for Deciphera Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals Gross Profit Chart

Deciphera Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Profit

Get a 7-Day Free Trial

25.00

41.86

93.22

125.27

159.62

Deciphera Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Profit	Get a 7-Day Free Trial															33.10	32.96	38.13	42.03	46.51

Competitive Comparison of Deciphera Pharmaceuticals's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Deciphera Pharmaceuticals's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's Gross Profit falls into.

Deciphera Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Deciphera Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	163.356	-	3.732
	=	159.6

Deciphera Pharmaceuticals's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	48.294	-	1.785
	=	46.5

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $159.6 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Deciphera Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	46.5	/	48.294
	=	96.30 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Deciphera Pharmaceuticals (NAS:DCPH) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Deciphera Pharmaceuticals had a gross margin of 96.30% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Deciphera Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (NAS:DCPH) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

D05:Germany

Address

200 Smith Street, Waltham, MA, USA, 02451

Website

https://www.deciphera.com

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Executives

Jama Pitman	officer: SVP, Regulatory & Quality	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Daniel C. Martin	officer: Chief Commercial Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Thomas Patrick Kelly	officer: Chief Financial Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Matthew L Sherman	officer: EVP & Chief Medical Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dashyant Dhanak	officer: EVP & Chief Scientific Officer	C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Daniel Lee Flynn	officer: Chief Scientific Officer	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Franklin Stuart Friedman	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dennis Leo Walsh	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Brightstar Associates Llc	10 percent owner	1020 CENTRAL STREET, KANSAS CITY MO 64105
James Arthur Bristol	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Michael Douglas Taylor	director, officer: See Remarks	C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Patricia L Allen	director	C/O DECIPHERA PHARMACEUTICALS, INC, 200 SMITH STREET, WALTHAM MA 02451
Christopher John Morl	officer: Chief Business Officer	C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Ron Squarer	director	C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066